Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more

June 22, 2021 7:42 PM UTC

Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of targets through clinical proof of concept. CMO Walid Abi-Saab, who joined the company in late 2017 to oversee late-stage development, will be responsible for early-stage activities as the company searches for a successor. The announcement follows a series of clinical setbacks for the Belgian biotech. 

Kymera Therapeutics Inc. (NASDAQ:KYMR) hired Elaine Caughey as CBO. Caughey joins the protein degradation company from Cygnal Therapeutics Inc., where she was CBO. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article